

## Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019

October 22, 2019

CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 22, 2019-- <u>Lineage Cell Therapeutics</u>. <u>Inc.</u> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial Officer, will be presenting at the Dawson James Securities 5<sup>th</sup> Annual Small Cap Growth Conference on October 29<sup>th</sup>, 2019 at 4:05pm Eastern Time at the Wyndham Grand Hotel in the Preserve Ballroom in Jupiter, Florida.

Interested parties can access a live audio webcast on the <u>Events and Presentations</u> section of Lineage's website and an archived presentation will be available for 30 days.

## About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/lla development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/lla development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia®, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark. For more information, please visit <a href="www.lineagecell.com">www.lineagecell.com</a> or follow the Company on Twitter <a href="www.lineagecell.com">@ LineageCell.com</a> or follow the Company on Twitter

View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005025/en/

Source: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. IR Ioana C. Hone (<u>ir@lineagecell.com</u>) (510) 871-4188

Solebury Trout IR Gitanjali Jain Ogawa (Gogawa@troutgroup.com) (646) 378-2949